HomeCERS • NASDAQ
add
Cerus Corp
Previous close
$2.24
Day range
$2.01 - $2.19
Year range
$1.12 - $2.96
Market cap
392.82M USD
Avg Volume
1.39M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 57.75M | 13.66% |
Operating expense | 30.39M | 5.40% |
Net income | -2.18M | 13.37% |
Net profit margin | -3.78 | 23.79% |
Earnings per share | -0.01 | 0.00% |
EBITDA | -248.00K | 77.80% |
Effective tax rate | -5.76% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 82.88M | 3.02% |
Total assets | 221.86M | 10.42% |
Total liabilities | 156.89M | 8.94% |
Total equity | 64.96M | — |
Shares outstanding | 192.17M | — |
Price to book | 6.79 | — |
Return on assets | -0.73% | — |
Return on capital | -0.99% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -2.18M | 13.37% |
Cash from operations | 6.20M | 25.79% |
Cash from investing | -1.38M | 81.09% |
Cash from financing | -1.03M | -238.20% |
Net change in cash | 3.79M | 305.14% |
Free cash flow | 4.48M | -3.10% |
About
Cerus Corporation is an American multinational biotechnology company headquartered in Concord, California that develops and provides a treatment system to pathogen-reduce human blood products for the healthcare industry. Wikipedia
Founded
Sep 1991
Headquarters
Website
Employees
275
